Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
基本信息
- 批准号:10640074
- 负责人:
- 金额:$ 44.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-23 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AdherenceAdultAftercareAortaArteriesBiologicalBiological AvailabilityBlood PressureCaloric RestrictionCardiovascular DiseasesCardiovascular systemCause of DeathChronicChronic Kidney FailureClinicClinicalClinical TrialsCollagenComplicationConduct Clinical TrialsDementiaDepositionDevelopmentDouble-Blind MethodEffectivenessElasticityElderlyEventFemurFunctional disorderFutureGoalsHealthHourHumanHypertensionImpaired cognitionInflammationMeasuresMediatingMusMuscle TonusNatural SupplementNephrologyObesityOralOrganOverweightOxidative StressOxidative Stress InductionPathogenesisPatientsPeripheral Blood Mononuclear CellPersonsPhasePhysiologic pulsePhysiologicalPlacebo ControlPlacebosPopulationPrevention strategyProcessRandomizedRegimenRenal functionResearchResearch PriorityRiskRisk FactorsRisk ReductionSafetySiteSkeletal MuscleSmooth MuscleStrokeSupplementationTestingTranslatingVascular Smooth MuscleVasoconstrictor AgentsVentricular RemodelingWomanarterial stiffnessbone masscapsulecardiovascular disorder riskcardiovascular risk factorcirculating biomarkersclinically relevantcomorbiditydietingeffectiveness evaluationevidence basefemoral arteryhealth assessmentimprovedinsightmenmiddle agemimeticsmuscle formnicotinamide riboside supplementationnicotinamide-beta-ribosidenovelnutritionoral supplementationpharmacologicpressureprimary outcomerandomized placebo-controlled clinical trialreduced muscle massresponsesafety assessmentsecondary outcomestandard measurevasoconstriction
项目摘要
Project Summary
Risk of cardiovascular diseases (CVD) is significantly elevated in patients with chronic kidney disease (CKD);
however, this increased risk is only partially explained by traditional CV risk factors. Arterial dysfunction is an
important nontraditional CV risk factor gaining increased recognition in the field of nephrology. While many
changes likely contribute to the development of arterial dysfunction in patients with CKD, among those of
greatest concern is the development of stiffening of the large elastic arteries. This process is best represented,
both physiologically and pathophysiologically, by increases in the gold standard measure of arterial stiffening,
carotid to femoral artery pulse wave velocity (CFPWV), which reflects, in particular, increases in aortic
stiffness. Aortic stiffening with CKD is mediated by structural and functional (increased vascular smooth
muscle tone) changes in the arterial wall stimulated by oxidative stress and chronic low-grade
inflammation. Caloric restriction (CR) is a promising strategy for prevention of CKD-associated arterial
dysfunction and CVD. In this context, we have shown that CR reduces CFPWV and SBP in older mice and in
overweight/obese middle-age and older adults. However, long-term adherence to chronic CR regimens with
optimal nutrition is very difficult to achieve and unlikely to become clinically relevant in the near future as it may
reduce muscle and bone mass. As a result, we have since shown that boosting NAD+ bioavailability to
stimulate SIRT-1, a “CR mimetic” approach, reduces CFPW and oxidative stress in old mice, and we recently
took the first step in translating these findings in a study of middle-age and older adults with normal kidney
function and elevated systolic blood pressure (SBP). We found that supplementation with nicotinamide
riboside, a natural, commercially available precursor of NAD+ and novel CR mimetic, was well tolerated and
increased NAD+ bioavailability and reduced CFPWV and SBP. Here we propose a randomized, placebo-
controlled, double-blind, single-site phase IIa clinical trial to assess the safety and efficacy of oral
nicotinamide riboside (500 mg capsules 2x/day; NIAGEN®; ChromaDex Inc.) for 3 months vs. placebo
(n=59/group) for decreasing aortic stiffness and SBP in men and women (35-80 years) with stage III and IV
CKD. We hypothesize that treatment will be safe and well-tolerated, and will reduce CFPWV and SBP, as
related to increases in systemic NAD+ bioavailability and reductions in oxidative stress, inflammation and
vasoconstrictor factors.
Aim 1: To measure CFPWV (primary outcome) before/after nicotinamide riboside vs. placebo treatment;
Aim 2: To measure casual and 24h-ambulatory SBP (secondary outcome) before and after treatment;
Aim 3: To determine the safety and tolerability of treatment with nicotinamide riboside vs. placebo;
Aim 4: To measure systemic NAD+ and NAD+–related metabolite concentrations, as well as circulating
markers of oxidative stress, inflammation, and vasoconstriction factors before and after treatment.
项目摘要
慢性肾脏疾病(CKD)患者患心血管疾病(CVD)的风险显著增加;
然而,这种增加的风险只能用传统的简历风险因素部分解释。动脉功能障碍是一种
重要的非传统心血管危险因素在肾脏病领域得到越来越多的重视。虽然很多人
这些变化可能有助于CKD患者动脉功能障碍的发展,其中
最令人担忧的是大的弹性动脉硬化的发展。这一过程得到了最好的代表,
在生理和病理生理学上,通过动脉硬化黄金标准的增加,
颈动脉到股动脉的脉搏波速度(CFPWV),它特别反映了主动脉中的增加
僵硬。CKD患者的主动脉硬化是由结构和功能(增加的血管平滑度)介导的
肌肉张力)氧化应激和慢性低度损伤刺激的动脉壁改变
发炎。热量限制(CR)是预防CKD相关动脉疾病的一种有前景的策略
功能障碍和心血管疾病。在这种情况下,我们已经证明CR可以降低老年小鼠的CFPWV和SBP。
超重/肥胖的中老年人。然而,长期坚持慢性CR方案与
最佳营养是很难实现的,而且在不久的将来不太可能成为临床相关的,尽管它可能
减少肌肉和骨量。因此,我们已经证明,提高NAD+的生物利用度
刺激SIRT-1,一种类似CR的方法,可以减少老年小鼠的CFPW和氧化应激,我们最近
在一项肾脏正常的中老年人的研究中,第一步将这些发现转化为
收缩压(SBP)升高。我们发现补充烟酰胺
核糖苷是一种NAD+的天然、商用前体和新型CR模拟物,耐受性良好,
提高NAD+的生物利用度,降低CFPWV和SBP。在这里,我们提出一种随机的安慰剂-
评价口服的安全性和有效性的对照、双盲、单部位IIa期临床试验
烟酰胺核苷(500毫克胶囊,每天2次;NIAGEN®;ChromaDex Inc.)3个月与安慰剂对照
(n=59/组)用于降低III和IV期男性和女性(35-80岁)的主动脉僵硬和SBP
CKD。我们假设治疗将是安全和耐受性良好的,并将降低CFPWV和SBP,如
与增加全身NAD+生物利用度和减少氧化应激、炎症和
血管收缩因子。
目的1:比较烟酰胺核苷与安慰剂治疗前后的CFPWV(主要结果);
目的2:测定治疗前后随机和24小时动态SBP(次要结局);
目的3:比较烟酰胺核苷与安慰剂治疗的安全性和耐受性;
目的4:测量全身NAD+和NAD+相关代谢物浓度以及循环
治疗前后氧化应激、炎症和血管收缩因子的标志物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michel Benjamin Chonchol其他文献
Michel Benjamin Chonchol的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michel Benjamin Chonchol', 18)}}的其他基金
Clonal hematopoiesis, mild cognitive impairment and kidney function decline
克隆性造血、轻度认知障碍和肾功能下降
- 批准号:
10464393 - 财政年份:2022
- 资助金额:
$ 44.44万 - 项目类别:
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
- 批准号:
10534531 - 财政年份:2022
- 资助金额:
$ 44.44万 - 项目类别:
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
- 批准号:
10684097 - 财政年份:2022
- 资助金额:
$ 44.44万 - 项目类别:
Clonal hematopoiesis, mild cognitive impairment and kidney function decline
克隆性造血、轻度认知障碍和肾功能下降
- 批准号:
10626828 - 财政年份:2022
- 资助金额:
$ 44.44万 - 项目类别:
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease
吸气肌力量训练可降低患有慢性肾病的中年和老年人的收缩压
- 批准号:
10669712 - 财政年份:2021
- 资助金额:
$ 44.44万 - 项目类别:
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease
吸气肌力量训练可降低患有慢性肾病的中年和老年人的收缩压
- 批准号:
10313126 - 财政年份:2021
- 资助金额:
$ 44.44万 - 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
- 批准号:
10400032 - 财政年份:2019
- 资助金额:
$ 44.44万 - 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
- 批准号:
9762288 - 财政年份:2019
- 资助金额:
$ 44.44万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 44.44万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 44.44万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 44.44万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 44.44万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 44.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 44.44万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 44.44万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 44.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 44.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 44.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)